78079-08-0

Basic information

• Product Name: 4-Bromo-4'-sulfobiphenyl
• Synonyms: 4-Bromo-4'-sulfobiphenyl
• CAS NO: 78079-08-0
• Molecular Formula: C₁₂H₉BrO₃S
• Molecular Weight: 313.16706
• Mol File: 78079-08-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Bromo-4'-sulfobiphenyl(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-4'-sulfobiphenyl(78079-08-0)
• EPA Substance Registry System: 4-Bromo-4'-sulfobiphenyl(78079-08-0)

Safety Data

• Hazardous Substances Data: 78079-08-0(Hazardous Substances Data)

Upstream product

• 92-66-0 4-bromo-1,1'-biphenyl 
• 13610-11-2 [4'-Bromo-(1,1'-biphenyl)-4-yl]-sulfonyl chloride 

Downstream Products

• 59748-15-1 4'-n-pentyloxybiphenyl-4-carboxylic acid 
• 52364-71-3 4'-(pentyloxy)-4-biphenylcarbonitrile 
• 1027554-34-2 (S)-2-(4'-Bromo-biphenyl-4-sulfonylamino)-6-(3-phenyl-propionylamino)-hexanoic acid methyl ester 
• 1053654-35-5 (S)-2-(4'-Bromo-biphenyl-4-sulfonylamino)-5-(3-phenyl-propionylamino)-pentanoic acid methyl ester 
• 1026853-36-0 2-(4'-bromo-biphenyl-4-sulfonylamino)-3-phenyl-propionic acid tert-butyl ester 

Relevant articles and documents

AMPK ACTIVATORS

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone dea

ARYLENE FLUORINATED SULFONIMIDE COMPOSITIONS

Described herein are aromatic sulfonimide compositions that can be used to prepare polymers useful as membranes in electrochemical cells.

Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption

Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfona

ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS

The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: [Inser

Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

Compounds of formula (I), wherein G1 is CH or N; G2 is CH or N; R1 is a variety of optional substituents, L1 is (1-4C)alkylene; T1 is CH or N; R2 and R3 are independently hydroge

Hetero-substituted metalloprotease inhibitors

Heterocyclic substituted compounds having the general structure: which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes.

BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS

Compounds of formula (I) wherein R includes alkyl, halo, nitro, amino, cyano, alkoxy, and alkoxycarbonyl; R is alkyl and substituted alkyl; and R is OH or NHOH, are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, p

Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors

A series of biphenylsulfonamide derivatives of (S)-2-(biphenyl-4- sulfonylamino)-3-methylbutyric acid (5) were prepared and evaluated for their ability to inhibit matrix metalloproteinases (MMPs). For this series of compounds, our objective was to systematically replace substituents appended to the biphenyl and α-position of 5 with structurally diverse functionalities to assess the effects these changes have on biological and pharmacokinetic activity. The ensuing structure-activity relationship (SAR) studies showed that biphenylsulfonamides substituted with bromine in the 4'- position (11c) significantly improved in vitro activity and exhibited superior pharmacokinetics (C(max), t(1/2), AUCs), relative to compound 5. Varying the lipophilicity of the α-position by replacing the isopropyl group of 11c with a variety of substituents, in general, maintained potency versus MMP-2, -3, and -13 but decreased the oral systemic availability. Subsequent evaluation of its enantiomer, 11c', showed that both compounds were equally effective MMP inhibitors. In contrast, the corresponding hydroxamic acid enantiomeric pair, 16a (S-isomer) and 16a' (R-isomer), stereoselectivity inhibited MMPs. For the first time in this series, 16a' provided nanomolar potency against MMP-1, -7, and -9 (IC50'S = 110, 140, and 18 nM, respectively), whereas 16a was less potent against these MMPs (IC(50)'S = 24, 78, and 84 μM, respectively). However, unlike 11c, compound 16a' afforded very low plasma concentrations following a single 5 mg/kg oral dose in rat. Subsequent X-ray crystal structures of the catalytic domain of stromelysin (MMP-3CD) complexed with inhibitors from closely related series established the differences in the binding mode of carboxylic acid-based inhibitors (11c,c') relative to the corresponding hydroxamic acids (16a,a').

Biphenysulfonamide matrix metal alloproteinase inhibitors

Compounds of the formula STR1 wherein R1 includes alkyl, halo, nitro, amino, cyano, alkoxy, and alkoxycarbonyl; R2 is alkyl and substituted alkyl; and R3 is OH or NHOH are useful for inhibiting matrix metalloproteinase enz